Suppr超能文献

配体与大麻素受体 1(CB1)和大麻素受体 2(CB2)的结合模式和选择性。

Binding Modes and Selectivity of Cannabinoid 1 (CB1) and Cannabinoid 2 (CB2) Receptor Ligands.

机构信息

Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, United States.

Department of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, United States.

出版信息

ACS Chem Neurosci. 2020 Oct 21;11(20):3455-3463. doi: 10.1021/acschemneuro.0c00551. Epub 2020 Sep 30.

Abstract

The cannabinoid (CB) receptors (CBR and CBR) represent a promising therapeutic target for several indications such as nociception and obesity. The ligands with nonselectivity can be traced to the high similarity in the binding sites of both cannabinoid receptors. Therefore, the need for selectivity, potency, and G-protein coupling bias has further complicated the design of desired compounds. The bias of currently studied cannabinoid agonists is seldom investigated, and agonists that do exhibit bias are typically nonselective. However, certain long-chain endocannabinoids represent a class of selective and potent CBR agonists. The binding mode for this class of compounds has remained elusive, limiting the implementation of its binding features to currently studied agonists. Hence, in the present study, the binding poses for these long-chain cannabinoids, along with other interesting ligands, with the receptors have been determined, by using a combination of molecular docking and molecular dynamics (MD) simulations along with molecular mechanics-Poisson-Boltzmann surface area (MM-PBSA) binding free energy calculations. The binding poses for the long-chain cannabinoids implicate that a site surrounded by the transmembrane (TM)2, TM7, and extracellular loop (ECL)2 is vital for providing the long-chain ligands with the selectivity for CBR, especially I267 of CBR (corresponding to L182 of CBR). Based on the obtained binding modes, the calculated relative binding free energies and selectivity are all in good agreement with the corresponding experimental data, suggesting that the determined binding poses are reasonable. The computational strategy used in this study may also prove fruitful in applications with other GPCRs or membrane-bound proteins.

摘要

大麻素(CB)受体(CBR 和 CBR)代表了多种适应症(如疼痛和肥胖)的有前途的治疗靶点。非选择性配体可追溯到两种大麻素受体结合位点的高度相似性。因此,对选择性、效力和 G 蛋白偶联偏倚的需求进一步使所需化合物的设计复杂化。目前研究的大麻素激动剂的偏倚很少被研究,而表现出偏倚的激动剂通常是非选择性的。然而,某些长链内源性大麻素代表了一类选择性和有效的 CBR 激动剂。这类化合物的结合模式仍然难以捉摸,限制了其结合特征在当前研究的激动剂中的应用。因此,在本研究中,通过使用分子对接和分子动力学(MD)模拟以及分子力学-泊松-玻尔兹曼表面积(MM-PBSA)结合自由能计算的组合,确定了这些长链大麻素以及其他有趣配体与受体的结合构象。长链大麻素的结合构象表明,由跨膜(TM)2、TM7 和细胞外环(ECL)2 包围的位点对于为长链配体提供 CBR 的选择性至关重要,特别是 CBR 的 I267(对应于 CBR 的 L182)。基于获得的结合模式,计算的相对结合自由能和选择性与相应的实验数据非常吻合,表明确定的结合构象是合理的。本研究中使用的计算策略也可能在其他 GPCR 或膜结合蛋白的应用中证明是富有成效的。

相似文献

3
Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.大麻素在疼痛管理中的应用:CB1、CB2 和非经典受体配体。
Expert Opin Investig Drugs. 2014 Aug;23(8):1123-40. doi: 10.1517/13543784.2014.918603. Epub 2014 May 16.
9
Indoles and related compounds as cannabinoid ligands.吲哚及相关化合物作为大麻素配体。
Mini Rev Med Chem. 2008 Apr;8(4):370-87. doi: 10.2174/138955708783955935.
10
Highly Selective, Amine-Derived Cannabinoid Receptor 2 Probes.高选择性、胺衍生的大麻素受体 2 探针。
Chemistry. 2020 Jan 27;26(6):1380-1387. doi: 10.1002/chem.201904584. Epub 2020 Jan 21.

引用本文的文献

6
Recent Developments in Free Energy Calculations for Drug Discovery.药物发现中自由能计算的最新进展。
Front Mol Biosci. 2021 Aug 11;8:712085. doi: 10.3389/fmolb.2021.712085. eCollection 2021.

本文引用的文献

1
Cannabinoids and Cannabinoid Receptors: The Story so Far.大麻素与大麻素受体:迄今为止的故事。
iScience. 2020 Jul 24;23(7):101301. doi: 10.1016/j.isci.2020.101301. Epub 2020 Jun 20.
6
Crystal Structure of the Human Cannabinoid Receptor CB2.人源大麻素受体 CB2 的晶体结构
Cell. 2019 Jan 24;176(3):459-467.e13. doi: 10.1016/j.cell.2018.12.011. Epub 2019 Jan 10.
7
Cannabinoids and Pain: New Insights From Old Molecules.大麻素与疼痛:旧分子带来的新见解
Front Pharmacol. 2018 Nov 13;9:1259. doi: 10.3389/fphar.2018.01259. eCollection 2018.
8
Emerging Evidence for Cannabis' Role in Opioid Use Disorder.大麻在阿片类物质使用障碍中作用的新证据。
Cannabis Cannabinoid Res. 2018 Sep 1;3(1):179-189. doi: 10.1089/can.2018.0022. eCollection 2018.
9
Role of Cannabinoids in Obesity.大麻素在肥胖中的作用。
Int J Mol Sci. 2018 Sep 10;19(9):2690. doi: 10.3390/ijms19092690.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验